Etropal ADXBUL:ETR 50 OCF Yield % is -0.59 as of Jul. 12, 2026. GuruFocus rates XBUL:ETR with a GF Score™ of 50/100 and a GF Value™ of €8.59 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Etropal AD ranks worse than 60.45% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Etropal AD's OCF Yield % or its related term are showing as below:
XBUL:ETR'
s OCF Yield % Range Over the Past 10 Years
Min: -4.03 Med: 1.98 Max: 3.24
Current: -0.59
During the past 13 years, the highest OCF Yield % of Etropal AD was 3.24%. The lowest was -4.03%. And the median was 1.98%.
XBUL:ETR's OCF Yield % is ranked worse than 60.45% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 1.7
vs XBUL:ETR: -0.59
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Etropal AD OCF Yield % Related Terms
Etropal AD OCF Yield % Historical Data
* Premium members only.
The historical data trend for Etropal AD's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XBUL:ETR vs ISRG, BDX, MDLN: OCF Yield % Comparison
For the Medical Instruments & Supplies subindustry, Etropal AD's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Etropal AD OCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Etropal AD's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Etropal AD's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Etropal AD (XBUL:ETR) has a OCF Yield % of -0.59 as of Jul. 12, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Etropal AD and its competitors. According to the industry distribution chart, Etropal AD ranks #515 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 60.4%.
Is Etropal AD's OCF Yield % too high?
Etropal AD's current OCF Yield % is -0.59. Based on the distribution chart, Etropal AD ranks #515 out of 852 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Etropal AD has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Etropal AD's OCF Yield % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Etropal AD ranks #515 out of 852 companies for OCF Yield %. This places Etropal AD in the lower half of its industry. The industry median OCF Yield % is 1.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Devices & Instruments company?
The median OCF Yield % among Medical Devices & Instruments companies is 1.70, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Etropal AD and its competitors. For the Medical Devices & Instruments industry, the median OCF Yield % is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Etropal AD's current OCF Yield % is -0.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Etropal AD stock overvalued right now?
Based on GuruFocus' analysis, Etropal AD (XBUL:ETR) is currently considered Significantly Undervalued. The stock's GF Value™ is €8.59, compared to a current price of €2.52 — trading 70.7% below its estimated fair value. The current OCF Yield % is -0.59. Etropal AD's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Etropal AD (XBUL:ETR), the current OCF Yield % is -0.59 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Etropal AD (XBUL:ETR) Overvalued in 2026?
Based on GuruFocus' analysis, Etropal AD stock appears to be undervalued.
The current stock price of €2.52 is trading 70.7% below its estimated GF Value™ of €8.59.
GuruFocus considers Etropal AD to be Significantly Undervalued.
Key valuation signals for XBUL:ETR:
OCF Yield %: -0.59
GF Value™: €8.59 vs. price of €2.52 (70.7% below fair value)
No single metric tells the full story. See the XBUL:ETR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Etropal AD is engaged in the business of manufacturing medical accessories. The product portfolio includes fistula needles, blood taking sets, transfusion and infusion sets, catheters and tubes, urine collecting bags, colostomy bags, among others. The company also produces hip - joint endoprosthesis and instruments of implantation.
50GF Score
Get the complete analysis for XBUL:ETR
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XBUL:ETR has been successfully added to your 
